$2.31
0.0%
Downside
Day's Volatility :0.43%
Upside
0.43%
68.4%
Downside
52 Weeks Volatility :88.32%
Upside
63.04%
Period | Augmedix Inc | Index (Russel 2000) |
---|---|---|
3 Months | 171.0% | 0.0% |
6 Months | -40.0% | 0.0% |
1 Year | -51.06% | 0.0% |
3 Years | -34.0% | -22.3% |
Market Capitalization | 114.2M |
Book Value | $0.21 |
Earnings Per Share (EPS) | -0.47 |
Wall Street Target Price | 3.52 |
Profit Margin | -46.23% |
Operating Margin TTM | -63.85% |
Return On Assets TTM | -30.61% |
Return On Equity TTM | -329.78% |
Revenue TTM | 51.6M |
Revenue Per Share TTM | 1.03 |
Quarterly Revenue Growth YOY | 26.8% |
Gross Profit TTM | 14.0M |
EBITDA | -22.5M |
Diluted Eps TTM | -0.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.53 |
EPS Estimate Next Year | -0.47 |
EPS Estimate Current Quarter | -0.13 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 52.38%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 14.1M | - |
Net Income | -22.4M | - |
Net Profit Margin | -158.5% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 16.5M | ↑ 16.84% |
Net Income | -14.7M | ↓ 34.1% |
Net Profit Margin | -89.41% | ↑ 69.09% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 22.2M | ↑ 34.47% |
Net Income | -17.2M | ↑ 16.44% |
Net Profit Margin | -77.42% | ↑ 11.99% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 30.9M | ↑ 39.56% |
Net Income | -26.5M | ↑ 54.59% |
Net Profit Margin | -85.76% | ↓ 8.34% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 44.9M | ↑ 45.01% |
Net Income | -19.2M | ↓ 27.73% |
Net Profit Margin | -42.74% | ↑ 43.02% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.8M | ↑ 0.0% |
Net Income | -5.8M | ↑ 2.84% |
Net Profit Margin | -65.8% | ↓ 1.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.8M | ↑ 23.19% |
Net Income | -5.0M | ↓ 12.59% |
Net Profit Margin | -46.69% | ↑ 19.11% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 11.8M | ↑ 9.16% |
Net Income | -4.4M | ↓ 12.44% |
Net Profit Margin | -37.45% | ↑ 9.24% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.7M | ↑ 7.76% |
Net Income | -4.5M | ↑ 1.91% |
Net Profit Margin | -35.42% | ↑ 2.03% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 13.5M | ↑ 6.24% |
Net Income | -6.5M | ↑ 44.71% |
Net Profit Margin | -48.24% | ↓ 12.82% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 13.7M | ↑ 1.43% |
Net Income | -8.5M | ↑ 30.02% |
Net Profit Margin | -61.84% | ↓ 13.6% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 15.7M | - |
Total Liabilities | 80.9M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 27.9M | ↑ 77.49% |
Total Liabilities | 24.8M | ↓ 69.32% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 51.7M | ↑ 85.01% |
Total Liabilities | 28.0M | ↑ 12.85% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 33.6M | ↓ 34.91% |
Total Liabilities | 32.2M | ↑ 14.91% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 66.7M | ↑ 98.31% |
Total Liabilities | 43.4M | ↑ 34.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.6M | ↑ 0.0% |
Total Liabilities | 32.2M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 43.8M | ↑ 30.34% |
Total Liabilities | 39.9M | ↑ 23.88% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 40.8M | ↓ 6.88% |
Total Liabilities | 40.1M | ↑ 0.6% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 66.7M | ↑ 63.38% |
Total Liabilities | 43.4M | ↑ 8.21% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 59.6M | ↓ 10.73% |
Total Liabilities | 41.8M | ↓ 3.72% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 53.7M | ↓ 9.88% |
Total Liabilities | 43.2M | ↑ 3.4% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.9M | - |
Investing Cash Flow | -341.6K | - |
Financing Cash Flow | 22.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.6M | ↓ 26.39% |
Investing Cash Flow | -823.0K | ↑ 140.95% |
Financing Cash Flow | 17.2M | ↓ 22.49% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.4M | ↓ 1.68% |
Investing Cash Flow | -647.0K | ↓ 21.38% |
Financing Cash Flow | 26.4M | ↑ 53.87% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -18.6M | ↑ 29.12% |
Investing Cash Flow | -611.0K | ↓ 5.57% |
Financing Cash Flow | 37.8M | ↑ 43.19% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.8M | ↓ 9.78% |
Investing Cash Flow | -1.4M | ↑ 130.44% |
Financing Cash Flow | -1.2M | ↓ 103.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.4M | ↑ 0.0% |
Investing Cash Flow | -173.0K | ↓ 70.78% |
Financing Cash Flow | 7.0K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.0M | ↑ 35.75% |
Investing Cash Flow | -1.3M | ↑ 652.6% |
Financing Cash Flow | 11.9M | ↑ 169671.43% |
Sell
Neutral
Buy
Augmedix Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Augmedix Inc | 2.67% | -40.0% | -51.06% | -34.0% | -34.0% |
![]() Solventum Corp | 18.43% | -4.2% | -4.2% | -4.2% | -4.2% |
![]() Doximity, Inc. | 42.51% | 26.66% | 54.18% | -63.01% | -31.43% |
![]() Veeva Systems Inc. | 18.46% | -6.2% | -2.75% | -30.3% | 49.39% |
![]() Ge Healthcare Technologies Inc. | 7.25% | -8.17% | 29.12% | 40.67% | 40.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Augmedix Inc | NA | NA | NA | -0.53 | -3.3 | -0.31 | NA | 0.21 |
![]() Solventum Corp | NA | NA | NA | 6.26 | 0.17 | 0.08 | NA | NA |
![]() Doximity, Inc. | 45.43 | 45.43 | 2.42 | 0.9 | 0.17 | 0.11 | NA | 4.92 |
![]() Veeva Systems Inc. | 57.42 | 57.42 | 1.39 | 4.76 | 0.13 | 0.06 | NA | 32.04 |
![]() Ge Healthcare Technologies Inc. | 25.23 | 25.23 | 2.26 | 4.24 | 0.21 | 0.06 | 0.0 | 17.08 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Augmedix Inc | Buy | $114.2M | -34.0% | NA | -46.23% |
![]() Solventum Corp | Hold | $10.8B | -4.2% | NA | 15.73% |
![]() Doximity, Inc. | Hold | $6.7B | -31.43% | 45.43 | 32.53% |
![]() Veeva Systems Inc. | Buy | $35.0B | 49.39% | 57.42 | 23.91% |
![]() Ge Healthcare Technologies Inc. | Buy | $39.9B | 40.67% | 25.23 | 8.1% |
Insights on Augmedix Inc
Revenue is up for the last 17 quarters, 3.72M → 13.66M (in $), with an average increase of 7.7% per quarter
Netprofit is down for the last 4 quarters, -4.40M → -8.45M (in $), with an average decrease of 25.6% per quarter
In the last 1 year, Doximity, Inc. has given 54.2% return, outperforming this stock by 105.3%
Redmile Group, LLC
Samjo Management LLC
Perkins Capital Management Inc
Vanguard Group Inc
Balyasny Asset Management LLC
Rhenman Partners Asset Management AB
augmedix is a telemedicine charting service for healthcare providers that eliminates the 17 hours each week providers spend on ehr documentation. using wearable technology to connect their clinic with the augmedix charting service, providers can focus on what they do best: taking care of patients.
Organization | Augmedix Inc |
Employees | 1430 |
CEO | Mr. Emmanuel Krakaris |
Industry | Miscellaneous |
A Spac I Acquisition Corp
$2.31
+0.0%
Keyarch Acquisition Corp
$2.31
+0.0%
Connexa Sports Technologies Inc
$2.31
+0.0%
Us Value Etf
$2.31
+0.0%
First Wave Biopharma Inc
$2.31
+0.0%
Global X Msci Next Emerging
$2.31
+0.0%
Fat Projects Acquisition Corp
$2.31
+0.0%
Capital Link Global Fintech
$2.31
+0.0%
Applied Uv Inc
$2.31
+0.0%